Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis Williams

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Journal of Experimental & Clinical Cancer Research : CR|December 3, 2021
Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancerHussein Ghamlouch, Eileen M Boyle, Patrick Blaney, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 3, 2024
Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapyDanai Dima, Michael Hughes, Mark Orland, et al.
British Journal of Haematology|January 24, 2024
Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre studyDanai Dima, Aliya Rashid, James A Davis, et al.
Blood Cancer Journal|August 1, 2025
Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myelomaMobina Golmohammadi, Shahzad Raza, Maram Albayyadhi, et al.
Blood Cancer Journal|May 31, 2022
Structural variants shape the genomic landscape and clinical outcome of multiple myelomaCody Ashby, Eileen M Boyle, Michael A Bauer, et al.
Blood Cancer Journal|May 31, 2024
Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell TherapyDanai Dima, Al-Ola Abdallah, James A Davis, et al.
Seminars in Cell & Developmental Biology|May 7, 2021
Chromothripsis as a pathogenic driver of multiple myelomaFrancesco Maura, Eileen M Boyle, Even H Rustad, et al.
Hematological Oncology|June 14, 2024
Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathyDanai Dima, Utkarsh Goel, Aishwarya Sannareddy, et al.
Transplantation and Cellular Therapy|June 10, 2026
Neighborhood socioeconomic disadvantage and distance from treatment center do not impact survival outcomes of patients with non-Hodgkin lymphoma and multiple myeloma treated with CAR T-cell therapiesAgrima Mian, Rafaella Litvin, Danai Dima, et al.
Blood Advances|February 3, 2019
Invariant phenotype and molecular association of biallelic <i>TET2</i> mutant myeloid neoplasiaHassan Awada, Yasunobu Nagata, Abhinav Goyal, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Journal of Experimental & Clinical Cancer Research : CR|December 3, 2021
Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancerHussein Ghamlouch, Eileen M Boyle, Patrick Blaney, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 3, 2024
Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapyDanai Dima, Michael Hughes, Mark Orland, et al.
British Journal of Haematology|January 24, 2024
Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre studyDanai Dima, Aliya Rashid, James A Davis, et al.
Blood Cancer Journal|August 1, 2025
Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myelomaMobina Golmohammadi, Shahzad Raza, Maram Albayyadhi, et al.
Blood Cancer Journal|May 31, 2022
Structural variants shape the genomic landscape and clinical outcome of multiple myelomaCody Ashby, Eileen M Boyle, Michael A Bauer, et al.
Blood Cancer Journal|May 31, 2024
Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell TherapyDanai Dima, Al-Ola Abdallah, James A Davis, et al.
Seminars in Cell & Developmental Biology|May 7, 2021
Chromothripsis as a pathogenic driver of multiple myelomaFrancesco Maura, Eileen M Boyle, Even H Rustad, et al.
Hematological Oncology|June 14, 2024
Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathyDanai Dima, Utkarsh Goel, Aishwarya Sannareddy, et al.
Transplantation and Cellular Therapy|June 10, 2026
Neighborhood socioeconomic disadvantage and distance from treatment center do not impact survival outcomes of patients with non-Hodgkin lymphoma and multiple myeloma treated with CAR T-cell therapiesAgrima Mian, Rafaella Litvin, Danai Dima, et al.
Blood Advances|February 3, 2019
Invariant phenotype and molecular association of biallelic <i>TET2</i> mutant myeloid neoplasiaHassan Awada, Yasunobu Nagata, Abhinav Goyal, et al.
Pageof 4